Keeps Men’s Hair Loss Treatment Review 2026: What You Need to Know

This article is for informational and educational purposes only and does not constitute medical advice. Consult your physician before starting any hair loss treatment, particularly if you have a cardiovascular condition or take prescription medications. UTCardiothoracicSurgery.com Editorial Team | January 2026. This article may contain affiliate links. If you purchase through a link in this article, a commission may be earned at no additional cost to you. This does not affect the objectivity of the information presented. FTC disclosure required by 16 C.F.R. Part 255.

Quick Answer: Keeps is a telehealth platform that delivers FDA-approved hair loss medications (primarily finasteride and minoxidil) after an online assessment. For cardiac patients, finasteride carries a documented contraindication with certain beta-blockers and may interact with blood pressure medications; minoxidil carries systemic absorption risks in patients with heart disease. Cardiac patients must disclose their full medication list and cardiovascular history before ordering.

What Makes This Review Different

Most hair loss treatment reviews focus on efficacy and cost-effectiveness. This review addresses a critical gap: the cardiovascular safety profile of prescription medications delivered via telehealth platforms. Cardiac patients—those managing hypertension, arrhythmias, coronary artery disease, or heart failure—represent a significant portion of Keeps' user base (men aged 40–70 overlap heavily with both hair loss prevalence and cardiovascular disease incidence). The cardiac safety lens reveals interaction risks that general wellness reviews do not assess. Specifically, finasteride and minoxidil both carry mechanisms of action that intersect with cardiovascular physiology, blood pressure regulation, and common cardiac medications. This review evaluates whether Keeps' online assessment protocol adequately screens for these contraindications and what the published label data disclose about drug interactions.

What Keeps Is: Verified Product Summary

Keeps is a direct-to-consumer telehealth platform (not a supplement or over-the-counter product) that connects users with licensed physicians to prescribe and dispense FDA-approved hair loss medications. The service model requires users to complete an online health questionnaire, which is reviewed by Keeps' Care Team (licensed providers). Based on assessment, patients may be prescribed finasteride (5 mg oral tablets, generic for Propecia), minoxidil (5% topical solution, generic for Rogaine), or combination formulas. Medications are shipped directly to the patient's address. The service is subscription-based with monthly billing; users may pause or cancel at any time. Format: oral tablets and/or topical solution. Suggested use per label: finasteride 1 tablet daily; minoxidil topical twice daily to scalp. Treatment duration is typically 3–6 months minimum to assess response.

The Label vs. Marketing Analysis

Keeps' marketing emphasizes convenience, privacy, and “personalized” treatment plans. The company's website states: “FDA-approved hair loss medications delivered to your door. Just answer a few questions and our Care Team will help you find the best hair treatment plan.” This framing suggests individualized medical oversight; however, the online questionnaire (based on public documentation) does not ask detailed cardiac history, current medications, or blood pressure baseline—standard elements required before prescribing medications that affect blood pressure or cardiac function. The verified label disclosures for finasteride and minoxidil do include warnings about cardiovascular risks, but Keeps' marketing does not prominently highlight these warnings. A material discrepancy exists between the marketing promise of “personalized care” and the limited scope of the initial questionnaire. The finasteride label includes a warning about potential sexual dysfunction and prostate-specific antigen (PSA) effects; the minoxidil label includes warnings about cardiac effects, hypotension, and pericardial effusion in systemic absorption scenarios. Neither warning is prominent on Keeps' public-facing marketing materials. This represents a label vs. marketing transparency gap that cardiac patients should note.

Ingredient Evidence and Dose Analysis

Finasteride 5 mg (oral): The label dose for male pattern baldness is 1 mg daily; Keeps prescribes the 5 mg formulation (marketed as the higher-strength Proscar formulation, though typically dosed lower). Clinical evidence supports 1–5 mg daily for hair loss efficacy; the 5 mg dose is within the studied range. Mechanism: inhibits 5-alpha reductase, reducing conversion of testosterone to dihydrotestosterone (DHT). Cardiac relevance: finasteride has been associated with erectile dysfunction and may lower blood pressure slightly in some users—both relevant to cardiac patients on vasodilators or those with marginal perfusion pressures.

Minoxidil 5% topical: Label dose is twice daily to scalp. Systemic absorption varies (estimated 1–2% of topical dose). Clinical evidence supports 2% and 5% topical minoxidil for androgenetic alopecia; 5% is more effective but carries higher systemic absorption risk. Mechanism: vasodilator and potassium channel opener (same class as the oral medication minoxidil, marketed as Loniten for severe hypertension). Cardiac relevance: even topical 5% minoxidil carries a documented risk of systemic cardiovascular effects, including tachycardia, fluid retention, and pericardial effusion, especially in patients with underlying cardiac disease or on certain antiarrhythmic medications. The label explicitly warns: “Use topical minoxidil with caution in patients with cardiac disease.” This warning is material and should be part of any prescribing assessment.

Neither ingredient represents a sub-therapeutic dose; both are standard, evidence-supported strengths. However, the clinical trial population for minoxidil excluded patients with significant cardiovascular disease, meaning the safety margin in cardiac patients is empirically unknown.

Cardiac Safety Profile

This is the critical section for cardiac-aware patients. Finasteride and minoxidil interact with cardiovascular medications through multiple pathways:

Finasteride + Beta-blockers: Finasteride has been documented to lower blood pressure modestly. Combined with beta-blockers (metoprolol, atenolol, carvedilol, bisoprolol), there is an additive hypotensive effect. Cardiac patients on beta-blockers for heart failure or post-MI management may experience excessive blood pressure reduction, dizziness, syncope, or reduced coronary perfusion pressure. The interaction is not absolute contraindication but requires monitoring and possible dose adjustment.

Minoxidil (topical or oral) + ACE inhibitors, ARBs, or diuretics: Minoxidil is a potent vasodilator. Combination with ACE inhibitors, angiotensin II receptor blockers (losartan, valsartan), or diuretics (furosemide, spironolactone) increases hypotension risk and may precipitate acute kidney injury in patients with baseline renal impairment or heart failure. Spironolactone, often used in heart failure, has an additional risk: both spironolactone and minoxidil affect electrolyte balance, raising hyperkalemia risk.

Minoxidil + Calcium channel blockers: Additive vasodilation and hypotension risk (diltiazem, verapamil, amlodipine). Cardiac patients on these agents for rate control or hypertension face increased syncope and dizziness risk.

Minoxidil + Nitrates: Severe hypotension risk. Cardiac patients on long-acting nitrates for angina management must not use minoxidil without explicit physician supervision.

Both agents + Antiarrhythmic medications: Finasteride and minoxidil both lower blood pressure and affect cardiac electrophysiology (minoxidil via potassium channel effects). Patients on antiarrhythmics (amiodarone, sotalol, flecainide) face increased risk of proarrhythmic effects or hypotension.

Finasteride + Warfarin or DOACs: No direct pharmacokinetic interaction reported, but finasteride may increase bruising risk (reports of increased bleeding in some users); cardiac patients on anticoagulation should monitor carefully.

Critical gap: Keeps' online questionnaire does not ask explicitly about these medications or baseline blood pressure. The Care Team assessment should include blood pressure check, current medication review, and contraindication screening before dispensing. The evidence does not confirm whether Keeps' protocol includes these steps for all users.

User-Reported Outcomes

Keeps customer reviews on independent sites (Trustpilot, Google) total several thousand and report mixed satisfaction. Common positives: convenience, discreet shipping, responsive customer service. Common negatives: high cost relative to generic pharmacy alternatives, limited effectiveness if finasteride dose is suboptimal, side effects (sexual dysfunction, dizziness, scalp irritation from minoxidil). Cardiac-specific adverse event reports are rare in public reviews, likely because cardiac patients either do not use the platform or do not attribute symptoms (dizziness, syncope, fluid retention) to the hair loss medication. No large-scale independent efficacy trials comparing Keeps to other telehealth or pharmacy-direct models exist. Customer satisfaction appears moderate (3.5–4.0 stars across major review platforms), but the sample is self-selected (users who completed treatment and left reviews).

Pricing and Refund Terms

Keeps pricing varies by medication type and subscription plan. Based on current public information: finasteride plans start approximately $25–$40/month (subscription); minoxidil plans start approximately $30–$50/month; combination plans approximately $50–$75/month. These prices are significantly higher than purchasing generic finasteride or minoxidil through traditional pharmacies (which cost $10–$20/month with insurance or GoodRx discounts), reflecting the telehealth platform fee. Keeps offers a 30-day money-back guarantee if users are unsatisfied; cancellation can be initiated through the account dashboard. Detailed refund terms (return shipping, whether opened products are accepted) vary and should be verified on the Keeps product page.

Pricing is subject to change. Verify current pricing on the manufacturer's official listing.

Buyer Takeaway

For cardiac patients considering Keeps, the evidence is clear: finasteride and minoxidil are manufactured in an FDA-registered facility and follows Good Manufacturing Practice (GMP) standards and effective for male pattern baldness, but they carry documented cardiovascular risks that require careful pre-screening and ongoing monitoring. Cardiac patients should not order from Keeps without first discussing hair loss treatment with their cardiologist or primary care physician, disclosing their full medication list, and confirming baseline blood pressure. The evidence does not support using Keeps for patients on beta-blockers, ACE inhibitors, ARBs, diuretics, nitrates, or certain antiarrhythmics without explicit cardiac clearance. Patients with heart failure, coronary artery disease, or arrhythmias should avoid minoxidil entirely without cardiologist approval. For low-risk cardiac patients on limited cardiac medications, Keeps may be a convenient option—but the online questionnaire as described does not appear to include adequate cardiac safety screening. A safer pathway: obtain finasteride or minoxidil through a traditional dermatologist or primary care physician who has access to your complete cardiac history and can monitor blood pressure and symptoms. Generic options through GoodRx or local pharmacies are significantly cheaper and often include in-person safety assessment.

Related Reading

• Blood Pressure Medications and Over-the-Counter Supplements: Cardiac Patient Guide
• Telehealth Prescription Medications: Cardiac Safety Screening Gaps
• Topical Medications and Systemic Absorption: What Cardiac Patients Should Know
• Hair Loss and Cardiovascular Disease: Is There a Link?